MARKET

RCKT

RCKT

Rocket Pharmaceu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.78
+1.72
+18.98%
After Hours: 10.95 +0.17 +1.58% 17:29 05/17 EDT
OPEN
9.45
PREV CLOSE
9.06
HIGH
10.80
LOW
9.45
VOLUME
1.26M
TURNOVER
0
52 WEEK HIGH
49.66
52 WEEK LOW
7.57
MARKET CAP
709.73M
P/E (TTM)
-4.0142
1D
5D
1M
3M
1Y
5Y
Needham & Co. Adjusts Price Target for Rocket Pharmaceuticals to $62 From $75, Reiterates Buy Rating
MT Newswires · 12h ago
Rocket Pharmaceuticals Presents Clinical Data From Danon Disease, Fanconi Anemia And Pyruvate Kinase Deficiency Programs At The 25Th Annual Meeting Of The American Society Of Gene And Cell Therapy
—      RP-A501 for Danon Disease well-tolerated in two pediatric patients with no complement-mediated toxicities reported; efficacy update remains on track for Q3
Benzinga · 1d ago
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
CRANBURY, N.J., May 16, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today a...
Business Wire · 1d ago
We Think Rocket Pharmaceuticals (NASDAQ:RCKT) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 6d ago
Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference
CRANBURY, N.J., May 11, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today a...
Business Wire · 6d ago
BRIEF-Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results
reuters.com · 05/05 22:43
Rocket Pharmaceuticals GAAP EPS of -$0.67 beats by $0.03
Rocket Pharmaceuticals press release (NASDAQ:RCKT): Q1 GAAP EPS of -$0.67 beats by $0.03. Cash position of $346.6M; operational runway extended into first half of 2024
Seekingalpha · 05/05 21:45
Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
CRANBURY, N.J., April 27, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Kinnari Patel, Pharm.D., MBA, Pre...
Business Wire · 04/27 11:00
More
No Data
Learn about the latest financial forecast of RCKT. Analyze the recent business situations of Rocket Pharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RCKT stock price target is 57.89 with a high estimate of 75.00 and a low estimate of 30.00.
High75.00
Average57.89
Low30.00
Current 10.78
EPS
Actual
Estimate
-0.63-0.47-0.32-0.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 191
Institutional Holdings: 68.25M
% Owned: 103.67%
Shares Outstanding: 65.84M
TypeInstitutionsShares
Increased
58
3.91M
New
25
1.66M
Decreased
44
3.78M
Sold Out
21
539.04K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.35%
Pharmaceuticals & Medical Research
+1.51%
Key Executives
Chairman/Director
Roderick Wong
President/Chief Operating Officer
Kinnari Patel
Chief Executive Officer/Director
Gaurav Shah
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance/Controller/Treasurer
John Militello
Chief Human Resource Officer/Senior Vice President
Isabel Carmona
Senior Vice President/Chief Compliance Officer/General Counsel
Martin Wilson
Other
Jonathan Schwartz
Director
Fady Malik
Independent Director
Elisabeth Bjork
Independent Director
Carsten Boess
Independent Director
Pedro Granadillo
Independent Director
Gotham Makker
Independent Director
David Southwell
Independent Director
Naveen Yalamanchi
No Data
No Data
About RCKT
Rocket Pharmaceuticals, Inc. is a clinical-stage, multi-platform biotechnology company that is focused on the development of gene therapies for rare and devastating diseases. The Company’s clinical-stage ex vivo lentiviral vector (LVV) programs include: Fanconi Anemia (FA), is a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; Leukocyte Adhesion Deficiency-I (LAD-I), is a genetic disorder that causes the immune system to malfunction; Pyruvate Kinase Deficiency (PKD), is a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia, and Infantile Malignant Osteopetrosis (IMO), is a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Webull offers kinds of Rocket Pharmaceuticals Inc stock information, including NASDAQ:RCKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCKT stock methods without spending real money on the virtual paper trading platform.